How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing.

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• Hereditary cancer susceptibility was traditionally assessed via single-gene or limited-gene testing based on patient history.
• Next-generation sequencing enables multigene panel testing, encompassing high, moderate, and low-penetrance genes.
• Germline mutations in cancer susceptibility genes can also be incidentally discovered through tumor molecular profiling.

Purpose of the Study:

• To compare single/limited gene testing with multigene panel testing for hereditary cancer susceptibility.
• To review considerations for choosing between targeted gene testing and broader panel approaches.
• To discuss germline risk implications arising from tumor molecular profiling.

Main Methods:

• Comparative analysis of genetic testing strategies (single/limited gene vs. multigene panels).
• Review of current literature and clinical guidelines regarding hereditary cancer testing.
• Discussion of challenges associated with characterizing novel or less-understood genes within panels.

Main Results:

• Multigene panels offer broader detection of hereditary cancer susceptibility but include genes with uncertain risk and management implications.
• Incidental germline findings during tumor profiling present unique challenges for genetic counseling and clinical management.
• The decision between testing strategies necessitates balancing comprehensive screening with the interpretation of complex genetic data.

Conclusions:

• Choosing between single/limited gene testing and multigene panels requires careful evaluation of gene penetrance, evidence, and clinical utility.
• Understanding the nuances of tumor molecular profiling is crucial for managing incidental germline findings.
• Advances in sequencing necessitate updated approaches to genetic counseling and hereditary cancer risk assessment.